Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
American Society of Clinical Oncology (ASCO)
Online
2022-02-19
DOI
10.1200/jco.21.02188
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis
- (2020) Kristen Pettit et al. BLOOD
- Management of myelofibrosis after ruxolitinib failure
- (2020) Claire N Harrison et al. ANNALS OF HEMATOLOGY
- Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
- (2019) Francesca Palandri et al. CANCER
- How we treat myelofibrosis after failure of JAK inhibitors
- (2018) Animesh Pardanani et al. BLOOD
- Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
- (2018) Claire N Harrison et al. Lancet Haematology
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis
- (2018) John Mascarenhas et al. JAMA Oncology
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2016) C N Harrison et al. LEUKEMIA
- Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) A. M. Vannucchi et al. ANNALS OF ONCOLOGY
- Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib
- (2015) K. P. Patel et al. BLOOD
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
- (2015) Catriona Jamieson et al. Journal of Translational Medicine
- A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
- (2015) A Pardanani et al. Blood Cancer Journal
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- JAK2V617F Drives Mcl-1 Expression and Sensitizes Hematologic Cell Lines to Dual Inhibition of JAK2 and Bcl-xL
- (2015) Jun Guo et al. PLoS One
- Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL, in patients with cancer
- (2014) J. Yang et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis
- (2014) P. S. Winter et al. Science Signaling
- Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
- (2013) A. Tefferi et al. BLOOD
- Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome
- (2013) BD Benites et al. Clinics
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
- (2013) Michaela Waibel et al. Cell Reports
- U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis
- (2012) A. Deisseroth et al. CLINICAL CANCER RESEARCH
- Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis
- (2012) Raquel Tognon et al. Journal of Hematology & Oncology
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement
- (2011) Ruben A. Mesa et al. CANCER
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- (2009) F. Passamonti et al. BLOOD
- The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis
- (2009) Ruben A. Mesa et al. LEUKEMIA RESEARCH
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More